Gastric Cancer Treatment Market size was valued at USD 9.5 billion in 2021 and is expected to reach USD 25.6 billion by 2028, at a CAGR of 15.3% during the forecast period 2022 to 2028. Sacral nerve stimulation (SNS) is a therapeutic electrical incitement treatment that is utilized to treat long haul entrail control and bladder control side effects through the adjustment of nerves controlling the lower urinary tract and pelvic floor. Gastric Cancer Market is becoming quickly because of expanding occurrence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors over the globe. Significant drivers for the Gastric Cancer Market are treatment progressions, combination therapies, expanding the number of growth treatment focuses, the extensive number of regulatory approvals for metastatic gastric disease and low measurement radiation innovation based devices. Moreover, the introduction of novel treatments for metastatic stomach disease is relied upon to drive the development of the Gastric Cancer market soon. However, the absence of sufficient monetary help from medical coverage strategies and stringent regulatory framewok for approving complex nature of radiation devices are the main considerations that can hamper the stomach malignancy advertise development over the figure time frame. Different factors, like, high cost of therapy and monetarily less accessibility of medications for the treatment of Gastric Cancer may hamper the worldwide high cost of therapy.